SC
HAE icon

Stephens Consulting’s Haemonetics HAE Stock Holding History

Stephens Consulting’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15
Closed -$954 – 1524
2025
Q1 		$954 Buy
+15
New +$1.02K ﹤0.01% 665

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Stephens Consulting's HAE Position: Q2 2025 in Review

Stephens Consulting sold out of Haemonetics (HAE) in Q2 2025, closing a stake of 15 shares — an estimated $954 sold.

Stephens Consulting first reported a position in HAE in Q1 2025 and held it in 1 quarter. The position peaked at $954 in Q1 2025. 298 funds tracked by Wall St. Rank hold HAE as of Q2 2025.

  • Stephens Consulting reported no remaining Haemonetics position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 15 Haemonetics shares in Q2 2025, an estimated $954.
  • Stephens Consulting first reported a position in Haemonetics in Q1 2025 and held it in 1 quarter.
  • Stephens Consulting's Haemonetics position peaked at $954 in Q1 2025.
  • 298 funds tracked by Wall St. Rank held Haemonetics as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.